MedTrace Logo

Monitoring Of Viral Load In Decentralised Area in Vietnam

NCT03249493 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 584

Last updated 2022-05-20

No results posted yet for this study

Summary

As of today, HIV-infected patients followed in decentralized area have little or even no access to viral load monitoring because laboratories able to perform this biological measurement are only in large cities, and because plasma transfer to these laboratories is complex and very costly.

Blood sampling using dried blood spots (DBS) could overcome these difficulties. The goal of this operational research is to document the feasibility of DBS use in decentralised area to monitor viral load, to evaluate the virological response on ART, and to compare the virological response between injecting drug users (IDU) and the other patients, as IDU represent a large proportion of HIV-infected patients who may have a lower access/adherence to care.

Conditions

Interventions

OTHER

Blood sample on DBS

We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards. HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results \> 1000 cp/mL

Sponsors & Collaborators

  • Global Fund

    collaborator OTHER

  • National Institute of Hygiene and Epidemiology, Vietnam

    collaborator OTHER

  • Hanoi University of Public Health

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Fabien TAIEB, MD · Institut Pasteur

  • Yoann Madec, PhD · Institut Pasteur

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2020-08-01
Completion
2020-09-01

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03249493 on ClinicalTrials.gov